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Abstract. The number of patients with malignant tumors has increased steadily. Every year more 
than 12 million new cases are registered, including non-Hodgkin's lymphoma. A modern problem 
in medicine consists of not only paraneoplastic processes accompanying the tumor, but a 
complication of anticancer therapy – neurotoxicity. This paper presents data on the occurrence 
and form of polyneuropathy in the peripheral T-cell lymphoma, and its main pathogenesis 
elements. Here the toxic effects of cytotoxic drugs and their role in the impairment of the nervous 
system have been described. 
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Аннотация. Число больных со злокачественными новообразованиями неуклонно 
возрастает. Ежегодно регистрируется более 12 миллионов новых случаев, среди которых 
не последнее место занимают неходжскинские лимфомы. Современной проблемой для 
медицины являются не только паранеопластические процессы, сопровождающие опухоль, 
но и осложнение противоопухолевой терапии – нейротоксичность. В статье приведены 
данные о встречаемости и форме полинейропатии при периферической Т-клеточной 
лимфоме, ее основных звеньях патогенеза. Описано токсическое действие цитостатиков и 
их роль в поражении нервной системы. 
Ключевые слова: полинейропатия; цитостатики; винкристин; периферическая  
Т-клеточная лимфома; онконевральные антигены; нейротоксичность. 
 
An impairment of the peripheral nervous system in 
malignant tumors, regardless of patient age, is still a 
significant problem with many unresolved issues the 
neurologists have faced with. In particular, there is the 
question remaining open of the differential diagnosis of 
paraneoplastic and post-chemotherapeutic disorders of the 
peripheral nervous system.  
The number of patients with malignant tumors has 
increased steadily worldwide. According to the experts’ 
calculations, more than 12 million new cases are detected 
yearly. Consequently, the overall death rate from cancer is 
expected to reach 7.6 mil. people annually (about 20,000 
deaths from cancer a day) [33].  It is known that lung 
cancer ranks first in male mortality, both in the Russian 
Federation and worldwide. Breast cancer ranks first in the 
female cancer morbidity in Russia [11]. However, one 
should not forget about less common cancer formations 
such as T-cell lymphomas, which are 12-15% of all types 
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of lymphomas, while the share of peripheral T-cell 
lymphomas accounts for 4-7% [15, 18]. According to 
statistics, peripheral T-cell lymphoma is detected in 1 case 
out of 100 thousand people per year [22].  Regardless of 
the features of the tumor development and progress, with 
rare exceptions, it is an aggressive type: the median overall 
survival of patients with the peripheral T-cell lymphoma in 
the basic CHOP-therapy (Cyclophosphamide, 
Hydroxyldaunomycine, Oncovin, Prednisolone) is 11-34 
months [3, 19, 22]. A T-cell phenotype is an independent 
factor of unfavorable prognosis [34]. 
Paraneoplastic polyneuropathy is approximately 1% 
of all types of polyneuropathy, but currently there is no 
sufficient data to confirm such a low statistics of this disease 
[6, 7, 9, 11, 13, 29, 31]. Thus, paraneoplastic polyneuropathy 
occurs in 5% of patients with cancer [6, 30, 31]. On the other 
hand, after analyzing the data from the literature, it was found 
that the impairment of the nervous system against lymphomas 
occurs quite often and reaches 5-29% of cases, and about 5-
10% impairs the peripheral nervous system (although, there 
are still no exact data on the statistics of peripheral T-cell 
lymphoma) [15, 30].  
It is known that the development of paraneoplastic 
polyneuropathy is associated not only with one of the 
following factors, such as compression of the nerves by the 
tumor itself, the impairment of the nervous system with 
either metastasis or side effects of radiotherapy, 
chemotherapy, or metabolic, vascular, hormonal changes, 
or opportunistic infections [1, 5, 7, 11, 31, 32]. It is more 
reasonable to stick to the multifactorial nature of the 
impairment of the peripheral nervous system. It is 
necessary to consider the fact that patients by the time of 
having recourse to the neurologist, in most cases, have 
already received at least one course of chemotherapy, 
because an immune mechanism of impairment occurs 
inseparably with both the toxic effects of drugs, and under 
the developed microcirculatory endothelial dysfunction 
that resulted in the nervous tissue hypoxia with further 
demyelination and axonal degeneration [4]. 
L. Thomas and F. Burnet described the basis of the 
pathogenesis of the cancer and nervous system interaction 
back in the mid-1950s in their concept of the immune 
response under cancer.  They suggested that immune 
mechanisms have an effect on tumor cells, inducing 
thereby the formation of anti-tumor antibodies, which 
damage the nerve cells [31].  
Based on the current visions of the immune system, it 
is assumed that paraneoplastic lesion of the peripheral 
nervous system can be caused by immunological processes 
that are provoked by the presence of tumor formation in 
cells and the cross-reactive antigens in the nervous system 
[1, 7, 9, 10, 11, 21, 29]. In some cases, the cells of 
malignant tumors start inexplicably to synthesize foreign 
substances (proteins), which are produced in normal 
conditions either within or on the surface of nerve cells. As 
a result, a synthesis of such neuronal proteins (so-called 
paraneoplastic antigens) in the tumor cells lying outside 
the nervous system causes the activation of the immune 
system, which in turn leads to the autoimmune response, 
i.e. to both production onconeural autoantibodies against 
the paraneoplastic antigens and, possibly, appearance of 
specific T-lymphocytes. Further, antibody-specific T-cells 
generated under the autoimmune response interact with the 
structures of the nervous system, which contain normal 
proteins identical in their structure to paraneoplastic 
antigens, that ultimately damages the neurons (including 
motor neurons of the anterior horns, and the spinal ganglia 
cells), and peripheral nerve fibers [1, 9, 10, 11, 12, 24, 31]. 
Onconeural autoantibodies are IgG, which, circulating in 
the patient’s blood, penetrate into the cerebrospinal fluid 
by passive diffusion, where they can attack the normal 
proteins identical to onconeural antigens, causing thereby 
the specific degeneration of the nervous system [8]. 
E. Day was the first to describe in 1965 the 
appearance of antigens specific to normal, non-
homologous to tumor, tissues in the malignant cells [25, 
30]. He called this phenomenon of antigenic divergence. 
Independently from E. Day, the researches of Institute of 
Cytology RAS also detected this phenomenon (Fel et al., 
1965, 1966) [25]. Antigens, which ensure the antigenic 
divergence, were identified as heteroorganic (in our case – 
onconeural antigens), namely the antigens typical of the 
tissues non-homologous to the tumor [30]. Currently, there 
is an active detection and investigation of onconeural 
antigens and the «response» antibodies synthesized by the 
immune cells. This is due to the fact that antibodies to 
onconeural antigens may appear in the blood well before a 
patient is diagnosed with cancer, and may thus serve as a 
very early diagnostic indicator of cancer formation and its 
possible paraneoplastic manifestations, both in the central 
nervous and in peripheral system [25].  
Some literature describes neurological deficit on the 
background of lymphomas (particularly, of peripheral T-
cell lymphoma) as a subacute, progressive flaccid 
tetraparesis that is a result of damage to the motor neurons 
of the spinal cord, followed by typical motor impairment, 
but with a much slighter manifestation of muscle 
fasciculations. There may also be the segmental damages 
to motor neurons with the development of paresis in 
individual muscle groups. More often phenomenon 
observed under peripheral T-cell lymphoma is an 
impairment of somatic nervous system [28, 31]. In this 
case, the clinical pattern includes motor polyneuropathy, 
for which the presence of pain and damage to the cranial 
nerves is unusual, with minimal sensitive dysfunction. 
Very rarely, the upper motoneuron of motor cortical areas 
may be involved in the process with the development of 
hyperreflexia, pathological appearance of symptoms 
(extensor stopnye symptoms, such as Babinski), and 
clonuses, even in the absence of metastases [28]. 
Speaking about the impairment of the peripheral 
nervous system on the background of malignancy, we 
should remember the specific systemic complications of 
chemotherapy such as neurotoxicity [8, 11, 20]  A large 
group of modern, highly effective anticancer drugs used in 
the treatment of cancer pathognomonic for paraneoplastic 
polyneuropathy, leads to clinically significant, dose-
limiting neurotoxicity, which requires the adjustment and 
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timely correction of dose, delay of the next cycles of 
chemotherapy, or discontinuation of treatment [11, 13, 23, 
26, 27].  According to the literature, 15-77.8% of cancer 
patients undergoing chemotherapy (and up to 100% of 
cases when treated with Vincristine) have the developing 
toxic polyneuropathy, which significantly complicates the 
prognosis for the underlying disease [2, 20]. 
Unfortunately, the mechanisms of peripheral 
neurotoxicity have not been fully determined yet. The 
most reasonable assumption is that the neurotoxicity 
manifestation is usually the result of an impaired axonal 
microtubular architectonics along with direct damage to 
the distal parts of axons (development of destructive 
axonopathy) [8, 9, 11, 13, 23, 26].  A diffuse or segmental 
demyelination of neurons – mielinopatiya, or degeneration 
of neuron bodies – neyronopatiya are observed less 
commonly [11, 16, 23, 26].    
The main pathogenetic element of the peripheral 
axonopathy is a damage to intracellular protein – tubulin, 
which plays a leading role in ensuring normal physiology 
of the nervous system [7, 8, 9, 13, 23, 26]. There is also 
evidence of involving the proteins such as kinesin and 
actin in the pathological process, with their subsequent 
damage [13, 23]. Comprehension of the pathogenesis of 
axonal degeneration of nerve fibers is based on the fact 
that the peripheral axons and spinal ganglia have no blood-
brain barrier, in contrast to the CNS. The cytostatic 
metabolites penetrate by direct diffusion into the nerve 
fibers from the surrounding interstitial fluid with their 
further accumulation there and damage to tubulin [7, 8, 9, 
13, 23, 26]. As a result, both the structure and function of 
microtubules is impaired and, consequently, axonopathy of 
sensory fibers occurs.  
The above pathological process explains also a 
preferential manifestation of neurosensory disorders in 
comparison with lack of motor activity during 
chemotherapy. The bodies of motor neurons are located in 
the anterior horns of the spinal cord, defending them from 
the influence of metabolites of antitubulin cytostatic agents 
with the use of blood-brain barrier mechanisms [23].  
Antineoplastic drugs from the group of vinca 
alkaloids, one of which is vincristine that causes 
depolymerization of microtubule tubulin, have serious 
damaging effect on the peripheral nervous system [14, 20, 
23, 26, 35]. Chemotherapy-induced peripheral sensory 
(sensorimotor less when high doses of the drug) 
polyneuropathy occurs as a result of vincristine therapy in 
43% -100% of patients undergoing a specific treatment of 
the underlying disease under basic treatment (in particular, 
peripheral T-cell lymphoma). This is a degenerative axonal 
neuropathy by the nature of damage.  The literature also 
mentions an extremely rare, empirically proved axonal-
demyelinating neuropathy, occurring under vincristine 
therapy: a cytostatic agent can affect Schwann cells and 
myelin sheath, as well as cause «pseudoaxonal» 
neuropathy with the axon-»ingrowing» Schwann cells with 
their further segregation into individual parts. The 
involvement of the nodes of Ranvier in the pathological 
process with their subsequent degeneration was 
experimentally recorded. Probably, the myelin sheath of 
the nerve can be damaged due to the toxic effect of 
cytostatic agent, secondary to axonopathy due to the 
autoimmune destruction and imbalance between 
demyelinating and reparative processes [20].  
The stimulation electroneuromyographic 
examinations of patients with malignant tumors, 
undergoing chemotherapy, allow clarifying the nature and 
degree of damage to peripheral nerve fibers. The most 
commonly revealed signs are ones of axonal damage to 
sensitive fibers in the form of reduced amplitude of 
sensory response and/or M-response under motor fibers 
lesion [20]. We should clarify that the motor disorders and, 
consequently, damage to the motor fibers detected at the 
stimulation electroneuromyography in vincristine-
receiving patients, were recorded 10 years after the end of 
the therapy [20, 36].  Increase in drug doses can lead to the 
demyelinating lesion of the nerve fibers manifesting itself 
in the reduced speed of nerve impulse and increased 
duration and latency of M-response [20]. 
Clinical signs of chemoinduced peripheral 
polyneuropathy occur a few weeks after the start of the 
chemotherapeutic treatment of the malignant neoplasm.   
Unlike most of other chemotherapy complications, the 
clinical signs of neurotoxicity are subjective and relate to 
neurosensory disorders in patients [11, 13, 23]. Peripheral 
neurosensory dysfunction may manifest itself as 
hypoesthesia, dysesthesia, numbness, paresthesias in the 
distal extremities, deterioration of proprioceptive, 
vibration, temperature and tactile sensitivity, sometimes 
with pain syndrome [11, 13, 20, 23].  The most typical of 
toxic damage to the peripheral nervous system with 
metabolites of cytostatic agents is a symmetric sensory 
neuropathy with lower extremities predominance. There 
may be development of a substantial limitation of routine 
activity of the patient, which is due to advanced cases of 
an underlying disease (inability to walk, write, using 
cutlery, etc.). Long after, there occur related disorders of 
motor function in the form of mild to moderate muscle 
weakness and muscle atrophy [23]. 
The direct damage to the cerebrospinal ganglia with 
metabolites of cytostatic agents leads to earlier appearance 
of neuronopathy symptoms rather than of axonopathy ones 
[26]. Timeframes differ significantly – a few hours or days 
after administration of cytostatics. Neurological deficit 
under neuropathy consists in both the lower and upper 
extremities impairment, a rapid loss of deep reflexes, 
muscle weakness, and there may be typical herpes sores in 
the corresponding dermatomes in this situation. Typically, 
damage to the spinal ganglia is associated with high doses 
of cisplatin and taxanes, especially when combined [23]. 
The action of the metabolites of anticancer drugs, 
particularly vincristine, along with peripheral neurotoxicity 
may result also in central neurotoxicity [23]. Several 
foreign and domestic authors describe its appearance in the 
clinical signs of cranial nerve impairment [14, 23, 35]. 
According to Bay A., a bilateral ptosis and an 
ophthalmoplegia may occur [35]. Dixit G. also describes 
the involvement of the cranial nerves into pathological 
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process during vincristine therapy, citing the specific 
anatomical structures such as optic, return, guttural, 
oculomotor, trochlear, and abducens nerves, as well as the 
symptoms upon their impairment in the form of a bilateral 
outer ophthalmoplegia, hoarseness, and short-term visual 
acuity reduction [17]. Perhaps, in this situation, an 
additional cranial pathology is a predictor of the 
chemoinduced polyneuropathy, which will allow the 
dedicated experts to adjust further treatment. 
Summary. After analyzing the literature data and the 
clinical case, we can state with assurance that it is quite 
difficult to determine the leading damaging component in 
the nervous system in patients undergoing chemotherapy 
for peripheral T-cell lymphoma.  
The emergence and rapid progression of 
neurosensory disorders in the extremities and occurrence 
of additional multiple craniopathy may be a predictor of 
clinical signs, being indicative of a toxic component of 
cytostatic agents in the development of chemoinduced 
polyneuropathy.  
As a rule, a polyneuropathy under peripheral T-cell 
lymphoma is of mixed nature, including both 
paraneoplastic and toxic components.  
The prognosis for axon-degenerating, chemoinduced 
peripheral polyneuropathy is unfavorable. 
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